Company news
Harbin Pharmaceutical Group Co., Ltd. Class A (SSE:600664) news
Harbin Pharmaceutical Group Co., Ltd. Class A news releases on 6ix. Latest, Aug 26, 2026: "Harbin Pharmaceutical Group Co., Ltd."Semi-annual Report for 2026
Press releases & updates
"Harbin Pharmaceutical Group Co., Ltd."Semi-annual Report for 2026
August 25, 2026
"Harbin Pharmaceutical Group Co., Ltd."Announcement on Abnormal Fluctuations in Stock Trading
August 11, 2026
"Harbin Pharmaceutical Group Co., Ltd."Announcement on the Proposed Selection in the 12th Batch of National Centralized Drug Procurement
August 3, 2026
"Harbin Pharmaceutical Group Co., Ltd."Announcement on the Affiliated Enterprise's Receipt of the Approval Notice for the Marketing Application of a Chemical API
July 29, 2026
"Harbin Pharmaceutical Group Co., Ltd."Announcement on Severe Abnormal Fluctuations in Stock Trading and Risk Warning
July 23, 2026
"Harbin Pharmaceutical Group Co., Ltd."Announcement on Resolutions of the 27th Meeting of the 10th Board of Directors
July 16, 2026
"Harbin Pharmaceutical Group Co., Ltd."Announcement on Adjustment to the Company's Products in the National Essential Medicines List
July 13, 2026
"Harbin Pharmaceutical Group Co., Ltd."Announcement on Expected Increase in Semi-annual Performance for 2026
July 9, 2026
Announcement on Pledge of Partial Shares of Controlling Shareholder
June 24, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
June 23, 2026
Announcement on Progress in Technology Transfer (Entrustment) Contract Signed by a Wholly-owned Subsidiary and Entry of Daprodustat Tablets into Phase III Clinical Trial (Confirmatory Clinical Study)
June 10, 2026
Notice on Convening the 2025 Annual General Meeting
June 2, 2026
Announcement on Attending the Online Collective Reception Day for Investors of Listed Companies in Heilongjiang Jurisdiction in 2026 and the 2025 Annual and Q1 2026 Performance Briefing
April 29, 2026
Announcement on Change of Accounting Policies
April 22, 2026
Announcement on Abnormal Fluctuations in Stock Trading
April 15, 2026
Announcement on Resolutions of the 24th Meeting of the 10th Board of Directors
March 9, 2026
Announcement on Subsidiary's Drug Passing the Consistency Evaluation for Generic Drugs
February 10, 2026
Announcement on Affiliated Enterprise Obtaining Approval for Marketing of Chemical APIs
February 5, 2026
Announcement on Subsidiary Obtaining Drug Registration Certificate
February 2, 2026
Announcement on Estimated Daily Related Party Transactions in 2026
January 26, 2026
Announcement on the Change of Quality Control Reviewer
January 21, 2026
Announcement on the Change of Signatory Certified Public Accountant and Quality Control Reviewer
January 7, 2026
Announcement on Resolutions of the 22nd Meeting of the 10th Board of Directors
December 24, 2025
Announcement on Reduction of Shares Held by the Company in Some of Holding Subsidiaries
November 19, 2025
Announcement on Resolutions of the 20th Meeting of the 10th Board of Directors
October 24, 2025
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
October 15, 2025
Announcement on Pledge Release and Re-pledge of Partial Shares Held by Controlling Shareholder
October 14, 2025
Announcement on Deferred Repurchase of Some Pledged Shares of Controlling Shareholders
October 10, 2025
Announcement on Discontinuation of the Board of Supervisors and Amendment to the "Articles of Association"
September 26, 2025
Announcement on Application for Increasing Comprehensive Credit Line to Financial Institutions in 2025
August 22, 2025
Announcement on the Listing and Leasing of Partial Idle Assets by Branch
August 4, 2025
Announcement on Pledge of Controlling Shareholders' Shares
July 22, 2025
Announcement on Release of Pledge of Partial Shares of Controlling Shareholders
July 4, 2025
Announcement on Resolution of the 2024 Annual General Meeting
June 20, 2025
Notice on Convening the 2024 Annual General Meeting
May 30, 2025
Announcement on Acquisition of Equity by Wholly-owned Subsidiary
May 15, 2025
Announcement on Attending the Online Collective Reception Day for Investors of Listed Companies in Heilongjiang Jurisdiction in 2025 and the 2024 Annual and Q1 2025 Performance Briefing
May 6, 2025
Announcement on Making Provisions for Asset Impairment in 2024
April 25, 2025
Announcement on "Corporate Value and Return Enhancement" Action Plan 2025
March 7, 2025
Announcement on Subsidiary's Drug Passing Consistency Evaluation of Quality and Efficacy of Generic Drugs
January 22, 2025
Announcement on Resolution of the 11th Meeting of the 10th Board of Directors
January 20, 2025
Clarification Announcement on Media Coverage
January 10, 2025
Announcement on Reversals for Asset Impairment
December 30, 2024
Announcement on Resolution of the 10th Meeting of the 10th Board of Directors
December 23, 2024
Announcement on Resolutions of the 5th Meeting of the 10th Board of Supervisors
October 25, 2024
Announcement on Convening the 2024 Semi-annual Performance Briefing
September 6, 2024
Announcement on Resolutions of the 4th Meeting of the 10th Board of Supervisors
August 22, 2024